Guan Xiaodong, Yang Mingchun, Man Chunxia, Tian Ye, Shi Luwen
School of Pharmaceutical Sciences, Peking University, Beijing, China.
International Research Center for Medicinal Administration, Peking University, Beijing, China.
Int J Health Plann Manage. 2018 Apr 30. doi: 10.1002/hpm.2537.
In an effort to relieve the pressure of drug shortages, the Chinese government implemented Low-price Medicines (LPM) policy to raise the price cap in July 2014. The purpose of this study is to examine the effect of the implementation of this policy on drug price in China. Price data of 491 LPM, including 218 low-price chemical medicines (LPCM) and 273 low-price traditional Chinese medicines (LPTCM), were collected from 699 hospitals. We used interrupted time series design to identify the variation of monthly Laspeyres Indexes (LI) and Paasche Indexes (PI) for LPM, LPCM, and LPTCM. The result demonstrated that although LPM expenditures increased, the proportion of LPM expenditures accounting for all medicine expenditures fell from 3.6% to 3.2%. After the implementation of LPM policy, there was a significant increasing trend in LPM-PI, LPCM-PI, and LPTCM-PI. The trend in LPM-LI and LPCM-LI was found from descending to rising. However, for LPTCM, the trend in the LI remained to decrease after the policy implementation. Despite the LPM policy had an increasing impact on the LPM drug price, the proportion of LPM expenditures accounting for all medicine expenditures did not increase. More efforts are needed in the future to promote the rational drug use in China.
为缓解药品短缺压力,中国政府于2014年7月实施低价药品政策以提高价格上限。本研究旨在考察该政策实施对中国药品价格的影响。从699家医院收集了491种低价药品的价格数据,其中包括218种低价化学药品和273种低价中药。我们采用间断时间序列设计来确定低价药品、低价化学药品和低价中药的月度拉氏指数(LI)和帕氏指数(PI)的变化。结果表明,尽管低价药品支出有所增加,但低价药品支出占所有药品支出的比例从3.6%降至3.2%。低价药品政策实施后,低价药品PI、低价化学药品PI和低价中药PI均呈现显著上升趋势。低价药品LI和低价化学药品LI的趋势由下降转为上升。然而,对于低价中药,政策实施后LI的趋势仍在下降。尽管低价药品政策对低价药品价格有上涨影响,但低价药品支出占所有药品支出的比例并未增加。未来需要做出更多努力来促进中国的合理用药。